Over the course of the forecast period, the legionnaire disease testing market is anticipated to grow at a 9% CAGR, from US$ 292 million in 2022 to US$ 819.5 million by 2032. A serious type of pneumonia infection that inflames the lungs is called legionnaire’s disease. The bacteria legionella is the cause of legionnaire’s disease. It is not possible to spread legionnaire’s disease. Inhaling polluted aerosols emitted by mists, jets, or water sprays is the most typical way that legionnaire’s disease is spread.
The increasing prevalence of legionnaire infections has increased the demand for better treatment and novel products, which has fueled the growth of legionnaire disease testing. The incubation period for legionnaire disease is 2-10 days, and severe pneumonia combined with untreated, respiratory or multi-organ failure can occur.
According to the Centers for Disease Control and Prevention, there are around 6,000 cases has been reported in the U.S. in the past few years. The disease prevalence has increased by 13% are more than it has been estimated. This rising patient pool is expected to boost the growth of legionnaire disease testing market.
Get a Sample Copy of the Report:
https://www.futuremarketinsights.com/reports/sample/rep-gb-10399
Legionnaire Disease Testing: Market Dynamics
Rising government initiatives and funding has led to increased awareness among the population regarding proper identification and management of the disease. Moreover, the growing prevalence rate increases the demand for advanced diagnostic methods are driving the legionella testing market globally.
The increasing adoption rate of legionnaire disease testing may drive the growth of the legionnaire disease testing market. Increasing R&D activities for technology development for various infections is further expected to drive the growth of the legionnaire disease testing market.
However, the lack of skilled professionals is expected to impede the growth of the legionnaire disease testing market. Additionally, lack of resources and unknowingness of infection are also expected to hamper the growth of legionnaire disease testing market.
Legionnaire Disease Testing: Overview
According to the World Health Organization, around 75-80% of the reported population are 50 years and above and out of which 65-70% are male population. The male population is more prone to legionnaire infection than the female population.
Additionally, the aging population is at high risk and more likely to infect by the legionella bacteria. However, the improvement of novel testing technologies is on the rise, globally. Increasing awareness about the available and developing technologies also contributing to increasing the adoption rate for the new testing method, which is expected to create a huge potential market for legionnaire disease testing.
However, lack of skilled healthcare physicians and unawareness of disease and unable to detect at an early stage may hamper the growth of legionnaire disease testing market. Moreover, the lack of advanced healthcare facilities may also restrict the growth of the legionnaire disease testing market.
Legionnaire Disease Testing: Region-wise Outlook
The Asia-Pacific legionnaire disease testing market is expected to grow at a high rate in the coming years. This is due to the presence of a large at high-risk population. Also, lack of awareness regarding the management of the infectious disease also contributing to the increasing number of population at risk in the region.
This is expected to create a high potential growth for the legionnaire disease testing market. The North America market is expected to be the most prominent legionnaire disease testing market due to advanced healthcare infrastructure and large research and development activities in the region.
Europe market will be at second place in the legionnaire disease testing market due to availability of skilled researchers coupled with a high adoption rate in the region. Latin America legionnaire disease testing market is expected to experience stable growth due to a lack of skilled professionals in the region.
The Middle East & Africa is expected to be the least lucrative legionnaire disease testing market due to lack of facilities and unawareness among the population regarding the legionnaire disease.
Legionnaire Disease Testing: Key Players
Some of the key players present in global legionnaire disease testing market are Beckman Coulter, Inc.; Albagaia Ltd.; Bio-Rad Laboratories, Inc.; Abbott Laboratories.; F. Hoffmann-La Roche AG; Thermo Fischer Scientific, Inc.; Becton, Dickinson and Company; Aquacert Ltd, BioMérieux SA; Idexx Laboratories Inc.; and others.
The regional analysis includes
•North America (U.S., Canada)
•Latin America (Mexico, Brazil, Rest of Latin America)
•Europe (Germany, Italy, U.K, Spain, France, Nordic countries, BENELUX, Russia, Rest of Europe)
•East Asia (China, Japan, South Korea)
•South Asia (India, Indonesia, Malaysia, Rest of East Asia)
•Middle East and Africa (N. Africa, S. Africa, Israel, Rest Of MEA)
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macroeconomic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies
Unlock Tailored Insights: Customize Your Report for Maximum Impact:
https://www.futuremarketinsights.com/customization-available/rep-gb-10399
Key Segments For Legionnaire Disease Testing Market
Legionnaire Disease Testing Segmentation by Product Type:
•Devices
•Polymerase Chain Reaction System
•Sequencer System
•Test Kits
•Assay Based Test Kits
•Rapid Test Kits
Legionnaire Disease Testing Segmentation by Diagnostic Test:
•Culture Method
•Urinary Antigen Test
•Paired Serology
•Direct Fluorescent Antibody (DFA) Stain
•Polymerase Chain Reaction (PCR)
•Combination Testing (Culture and Urinary Antigen Tests)
Legionnaire Disease Testing Segmentation by End User:
•Hospitals
•Diagnostic Laboratories
•Clinical Research Centers
•Academic Institutes
•Research Centers
•Others
Legionnaire Disease Testing Segmentation by Region:
•North America (U.S., Canada)
•Latin America (Mexico, Brazil)
•Europe (Germany, U.K., France, Italy, Spain, Poland, Russia)
•East Asia (China, Japan, South Korea)
•South Asia (India, Thailand, Malaysia, Vietnam, Indonesia)
•Oceania (Australia, New Zealand)
•Middle East & Africa (GCC Countries, Turkey, Northern Africa, South Africa)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
